The first patient in the Phase 3 clinical trial of a Melbourne-based drug company’s novel therapy for neovascular age-related macular degeneration (nAMD) has been treated in the US.
Read More
Australian optometry group acquired in $43 million deal
Australian optometry group The Optical Company (TOC) says it now has a clear mandate to expand its 41-store portfolio after announcing a multi-million-dollar deal to join a major Australasian allied health group.
Read More
Read More
Aussie firm reveals next-gen MIGS device in pipeline
Adelaide ophthalmic device manufacturer Nova Eye Medical is developing a next generation iTrack glaucoma surgical system to reduce operating times. It is also progressing towards a pivotal US study for its 2RT laser therapy for intermediate AMD that could fulfil a distinct gap in a multi-billion-dollar market.
Read More
Read More
Opthea becomes ASX top 300 company
Melbourne biopharmaceutical company Opthea has announced its inclusion on the ASX 300, just days after its lead drug candidate met primary end points in the latest clinical trial for diabetic macular edema (DME).
Read More
Read More
ACCC concludes investigation, clears Ellex-Lumibird deal
The Australian competition watchdog has cleared Ellex Medical Lasers’s $100 million sale of its laser and ultrasound business to Lumibird, with the transaction now expected to be completed as early as this week.
Read More
Read More